Step 1 of 2
Neoadjuvant therapy has evolved into a platform for prognosis, treatment selection, and therapeutic innovation in HER2-positive breast cancer. These slides review the evidence for removing anthracyclines from routine neoadjuvant treatment, eliminating carboplatin, and potentially replacing chemotherapy with targeted treatments. The current landscape of personalized neo/adjuvant treatment selection relies on factors including initial disease burden, previous treatments, and residual disease burden.